Navigation Links
Crucell's Rabies MAb Enters Phase I Trial in India

Dutch biotechnology company, Crucell N V’s Rabies monoclonal antibody (mAb) product has entered a phase I clinical study in India, four months after launching// a similar study in the US.

Crucell has developed a human monoclonal antibody product for the post-exposure prophylaxis of rabies, using Crucell’s MAbstract and Crucell’s PER.C6 technologies. This second phase I study is closely linked to the initial phase I study that is currently being performed in the US. Both studies are conducted under FDA authority, the Indian phase I study gained approval upon review by the Drug Controller-General of India (DCGI).

The clinical trial will be a randomized, double-blind, placebo controlled study in 44 healthy volunteers that will test the antibody product alone in a dose escalation as well as in combination with rabies vaccine. The study, funded by Crucell, will be conducted through a undisclosed clinical research organization in Mumbai, India. The main parameters under investigation will be safety, tolerability and rabies virus neutralizing activity.

“We are very pleased that would could initiate this second phase I trial, as it follows favorable interim safety and tolerability data from the initial US study. The clinical testing of the Rabies antibody cocktail in Asia is the next important step for the program, as the global burden of Rabies is mostly affecting this continent. In addition to clinical evaluation of the rabies mAb cocktail in India, we are currently exploring the conduct of clinical trials in other Asian countries, including China,” said Mr Jaap Goudsmit, Chief Scientific Officer at Crucell.

Dr Deborah Briggs, Director of the Alliance for Rabies Control opined that there is a tremendous need for additional sources of rabies immune globulins (RIG) throughout the world, especially in Asia where less than three percent of patients undergoing post-exposure prophylaxis actually receive passive immune produ cts. She said new mAb products similar to Crucell’s product will soon be available to help to solve the shortage problem and save human lives.

Source: BioSpectrumSRM
'"/>




Related medicine news :

1. Transfer Of Rabies Virus Possible From Organ Donor To Recipient
2. Rabies Requires Immediate Treatment
3. Student Bitten By Bat And Diagnosed With Rabies In Critical Condition
4. WB Asks Centre To Continue Supply Of Anti-Rabies Vaccine
5. Community Awareness Is Imperative For Eradication Of Rabies
6. Digital ID Chips Implanted in Dogs to Prevent Rabies
7. International Collaboration Takes Aim at Rabies
8. Bharat Biotech Launches Anti-Rabies Vaccine
9. WHO on an Anti Rabies and Snake Bite Mission
10. More Indians Die of Rabies Annually
11. New Vaccine to Tackle Rabies in Dogs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden Media ... All through the year, Garden Media aims to provide material helpful to clients’ goals ... pitching client’s key messages to gain coveted media placements, Garden Media wows ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet ... a conversation on the current obstacles facing infection prevention and offer strategies for ... caused by these infections. , The print component of “Fighting Infection” is ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017 Summary ... disease pipeline guide Primary Hyperoxaluria - Pipeline Review, ... Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline ... characterized by recurrent kidney and bladder stones. It ... oxalate. Symptoms include blood in the urine, pain ...
(Date:3/23/2017)... and VANCOUVER, British Columbia ... SPHS ) (the "Company" or "Sophiris"), a ... treatment of urological diseases, today announced that data from ... the drug as a focal treatment for localized prostate ... 26, 2017 at the 32 nd Annual European ...
(Date:3/23/2017)...   Icertis , the leading provider of ... today announced an upgrade to the Icertis Clinical ... clinical trials contract management. Built on the ... speeds up clinical trial contracting while improving collaboration ... "The pharmaceutical industry is under intense ...
Breaking Medicine Technology: